- 3,3,10,10-tetramethyl-1,2-dithia-5,8-diazacyclodeca-4,8-diene
-
The synthesis of C10H18N2S2 was described. It was observed that the molecule of the compound possess a local twofold axis and the arrangement of the S2N2 donor atoms in the macrocycle is anticlinal. The cyclic structure of the given compound is in contrast with the linear structure of the diamine-dithiol compound obtained from a reduction reaction. It was found that the H atoms bonded to C atoms were positioned geometrically in the compound.
- Lo, Jem-Mau,Mostafa, Golam,Chang, Ling-Yin,Liao, Fen-Ling,Lu, Tian-Huey
-
-
Read Online
- A Novel and Efficient Method for the Technetium-99m Labelling of Disulfide Compounds Using a Tetrahydroborate Exchange Resin
-
A novel and efficient method for the technetium-99m labelling of disulfide compound 7 was established with high radiochemical purity in which tetrahydroborate exchange resin (BER) simultaneously carries out the reduction of 7, the reduction of [99mTc]pertechnetate and chelation of 7 with technetium-99m. The labelling occurs in a one-pot three-step procedure that is amenable to the preparation of 99mTc-radiopharmaceuticals.
- Park, Sang Hyun,Gwon, Hui Jeong,Kim, Young Ho,Park, Kyung Bae
-
-
Read Online
- First examples of oxidizing aldehydes to carboxylic acids in the presence of a tertiary disulfide functional group: Synthesis of novel diacid-disulfides
-
The disulfide functionality exists in numerous organic compounds of interest in both chemistry and biology. In view of the fact that the disulfide function is highly susceptible to further oxidation by a broad range of agents, conducting a chemoselective
- Fang, Xinqin,Bandarage, Upul K.,Wang, Tiansheng,Schroeder, Joseph D.,Garvey, David S.
-
-
Read Online
- ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF
-
The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs) that target BRM for degradation, to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where BRM degradation is beneficial.
- -
-
Page/Page column 172
(2022/02/05)
-
- RADIOACTIVELY LABELED SUBSTANCE
-
Provided are: a radiolabeled drug, which is efficiently accumulated in a target and has high in vivo stability; and diagnosis and treatment each using the radiolabeled drug. Specifically provided are: a radiolabeled drug showing increased accumulation in a target site, which comprises a complex composed of a ligand that is bound to a compound capable of binding to a target molecule and forms a polycoordinated complex with a metal (e.g., technetium or rhenium) and a radionuclide of the metal; the radiolabeled drug for diagnosis or treatment; a ligand for preparing the radiolabeled drug; a kit that comprises a drug comprising the ligand and a drug comprising a radionuclide of a metal, as separate package units; and a method of increasing accumulation of a radiolabeled drug in a target site, comprising using the above-mentioned radiolabeled drug.
- -
-
-
- Radioactively Labeled Substance
-
Provided are: a radiolabeled drug, which is efficiently accumulated in a target and has high in vivo stability; and diagnosis and treatment each using the radiolabeled drug. Specifically provided are: a radiolabeled drug showing increased accumulation in a target site, which comprises a complex composed of a ligand that is bound to a compound capable of binding to a target molecule and forms a polycoordinated complex with a metal (e.g., technetium or rhenium) and a radionuclide of the metal; the radiolabeled drug for diagnosis or treatment; a ligand for preparing the radiolabeled drug; a kit that comprises a drug comprising the ligand and a drug comprising a radionuclide of a metal, as separate package units; and a method of increasing accumulation of a radiolabeled drug in a target site, comprising using the above-mentioned radiolabeled drug.
- -
-
-
- Nitrostated and nitrosylated prostaglandins, compositions and methods of use
-
The present invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.
- -
-
Page/Page column 42
(2008/06/13)
-
- Tc-labeled arylpiperazine derivatives for imaging serotonin receptor
-
The present invention relates to Tc-labeled arylpiperazine derivatives for imaging serotonin receptor and, more particularly, to arylpiperazine derivatives coupled with MAMA-disulfide, N2S2 or dimethyl-N2S2 chel
- -
-
Page/Page column 8
(2008/06/13)
-
- SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE
-
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
- -
-
Page/Page column 308
(2010/02/14)
-
- Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
-
The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.
- -
-
-
- Nitrosothiol esters of diclofenac: Synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs
-
Despite its widespread use, diclofenac has gastrointestinal liabilities common to nonsteroidal antiinflammatory drugs (NSAIDs) that might be reduced by concomitant administration of a gastrointestinal cytoprotectant such as nitric oxide (NO). A series of novel diclofenac esters containing a nitrosothiol (-S-NO) moiety as a NO donor functionality has been synthesized and evaluated in vivo for bioavailability, pharmacological activity, and gastric irritation. All S-NO-diclofenac derivatives acted as orally bioavailable prodrugs, producing significant levels of diclofenac in plasma within 15 rain after oral administration to mice. At equimolar oral doses, S-NO-diclofenac derivatives (20a-21b) displayed rat antiinfiammatory and analgesic activities comparable to those of diclofenac in the carrageenan-induced paw edema test and the mouse phenylbenzoquinone-induced writhing test, respectively. All tested S-NO-diclofenac derivatives (20a-21b) were gastric-sparing in that they elicited markedly fewer stomach lesions as compared to the stomach lesions caused by a high equimolar dose of diclofenac in the rat. Nitrosothiol esters of diclofenac comprise a novel class of NO-donating compounds having therapeutic potential as nonsteroidal antiinflammatory agents with an enhanced gastric safety profile.
- Bandarage,Chen,Fang,Garvey,Glavin,Janero,Letts,Mercer,Saha,Schroeder,Shumway,Tam
-
p. 4005 - 4016
(2007/10/03)
-
- Synthesis of β-CIT-BAT, a potential technetium-99m imaging ligand for dopamine transporter
-
The synthesis of an N2S2 conjugated BAT phenyltropane ligand is described. This agent can be further used to incorporate technetium-99m to form a neutral complex for SPECT imaging of the dopamine transporter.
- Tamagnan,Tamagnan, Gilles,Gao,Gao, Yigong,Baldwin,Baldwin, Ronald M.,Zoghbi,Zoghbi, Sami S.,Neumeyer,Neumeyer, John L.
-
p. 4353 - 4356
(2007/10/03)
-
- Rhenium complexes
-
Rhenium complexes of formula (I), radiolabelled complexes thereof or pharmaceutically acceptable salts thereof: STR1 wherein R is straight or branched chain C1-10 alkyl, C1-10 alkenyl, C1-10 alkynyl optionally substituted by cycloalkyl or aryl; C1-10 cycloalkyl optionally substituted by straight or branched chain alkyl, alkenyl, alkynyl or aryl; or aryl optionally substituted by straight or branched chain alkyl, alkenyl, alkynyl or cycloalkyl for use in liver cancer therapy and metastasis of cancer.
- -
-
-
- Triamine chelants, their derivatives, complexes and conjugates
-
A group of functionalized triamine chelants and their derivatives that form complexes with radioactive metal ions are disclosed. The complexes can be covalently attached to a protein or an antibody or antibody fragment and used for therapeutic and/or diag
- -
-
-
- New Thionitrites: Synthesis, Stability, and Nitric Oxide Generation
-
In order to study the influence of substitutions at the α and β carbon atoms on the stability of the S-NO bond, water-soluble thionitrites RSNO have been synthesized by nitrosation of cysteamine and mercaptoethanol derivatives and characterized. 1H and 13C NMR spectroscopies have proven to be excellent probes for the nitrosation of thiols.In water, at physiological pH, the compounds decomposed into nitric oxide NO and the corresponding disulfides.The rate at which NO was released was very sensitive to modifications at the α and β carbon atoms.Tertiary thionitrites were more stable than primary thionitrites.The β-substituents decreased the rates of decomposition in the following order: OH > NHCOCH3 > NH3(+).S-Nitrosocysteamine derivatives were greatly stabilized at low pH.The compounds described here might be convenient and useful as vehicles for spontaneous generation of nitric oxide in biological systems, at rates that can be finely tuned and controlled over a wide range.
- Roy, Beatrice,Moulinet d'Hardemare, Amaury du,Fontecave, Marc
-
p. 7019 - 7026
(2007/10/02)
-
- Novel radiopharmaceuticals and chelating agents useful in their preparation
-
A dihydropyridine←→ pyridinium salt type of redox, or chemical, delivery system for the site-specific and/or site-enhanced delivery of a radionuclide to the brain is provided. A chelating agent capable of chelating with a radionuclide and having a primary
- -
-
-
- Compounds for site-enhanced delivery of radionuclides and uses thereof
-
A dihydropyridine pyridinium salt type of redox, or chemical, delivery system for the site-specific and/or site-enhanced delivery of a radionuclide to the brain is provided. A chelating agent capable of chelating with a radionuclide and having a reactive hydroxyl, carboxyl, amino, amide or imide group is coupled to a carrier moiety comprising a dihydropyridine pyridinium salt nucleus and then complexed with a radionuclide to provide a new radiopharmaceutical that, in its lipoidal dihydropyridine form, penetrates the blood-brain barrier ("BBB") and allows increased levels of radionuclide concentration in the brain, particularly since oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt retards elimination from the brain while elimination from the general circulation is accelerated. This radionuclide delivery system is well suited for use in scintigraphy and similar radiographic techniques.
- -
-
-
- Age-resisting polymers and their preparation by reactions involving use of certain aminomercaptans
-
This invention relates to polymers which contain amino-sulfide age-resistant groups, and their preparation by reaction of aminomercaptans.
- -
-
-
- Preparation and Reactions of β-Oxosulfenyl Chlorides. II. Direct Chlorosulfenylation of Disubstituted Acetaldehydes by Sulfur Dichloride
-
The reaction of dialkylacetaldehydes (1a, b) with sulfur dichloride yields the corresponding β-oxosulfenylchlorides (2a, b).Examples for addition- and substitution-reactions of 2a, b are described.
- Muehlstaedt, Manfred,Meinhold, Hansjuergen,Martinetz, Dieter,Neumann, Eberhard
-
p. 631 - 638
(2007/10/02)
-